The outlook of companies tied to Viagra's legacy presents a complex investment picture . While the initial success generated substantial gains, generic alternatives have significantly diminished market share . Investing in related pharmaceutical companies now requires a thorough assessment of intellectual property safeguards, evolving medical trend